Command Palette

Search for a command to run...

Discover

5th Circuit Halts Telehealth Abortion Pill Access, Reinstates Pickup Rule

No image

A federal appeals court in New Orleans ordered a nationwide halt to telehealth prescribing and mail delivery of the abortion pill mifepristone on May 1, reinstating an in‑person pickup rule that had been lifted in 2023. The decision from a three‑judge panel of the 5th U.S. Circuit Court of Appeals affects what has become the most common method of ending a pregnancy in the United States, used in roughly two‑thirds of abortions. thehill +1

The ruling came in a lawsuit led by Louisiana’s Republican attorney general, arguing that the Food and Drug Administration overstepped when it allowed mifepristone to be prescribed via telemedicine and shipped to patients. The panel granted Louisiana a temporary stay that suspends the FDA’s 2023 rule nationwide while the case continues, a move that overrode a lower‑court judge who had paused the dispute to let the agency complete a review. thehill +2

What Changes for Patients and Providers Now?

Under the order, patients can still obtain mifepristone in states where abortion remains legal, but only by picking it up in person from a clinician rather than through telehealth visits and mail‑order pharmacies. nytimes +1 That immediately cuts off cross‑state telehealth services that had delivered an estimated 91,000 medication abortions to people living under total abortion bans in 2025, often under the protection of blue‑state “shield laws.” nature

Doctors and reproductive‑rights groups warned that the shift would hit hardest in rural areas and among patients who face barriers to travel, including low‑income people and those experiencing intimate partner violence. democracyforward +1 Clinicians also said the ruling could disrupt miscarriage management and other non‑abortion uses of mifepristone. GenBioPro, a generic manufacturer, called the decision “alarming” and said it ignored “decades of safe use,” vowing to pursue all legal avenues to restore access. nytimes +1

A Direct Challenge to FDA Authority, Headed Toward the Supreme Court

The panel’s opinion signaled a willingness to let states challenge federal drug regulation, rejecting arguments that courts should wait for the FDA’s ongoing review and that state officials lack standing. nbcnews +1 Legal scholars said that posture could open the door to wider attacks on the FDA’s authority well beyond abortion, reviving concerns first raised when a Texas judge tried to suspend mifepristone’s approval in 2023. time +1

Danco Laboratories, the brand‑name manufacturer, has asked the 5th Circuit for a seven‑day pause of the order so it can seek emergency relief from the U.S. Supreme Court. npr +1 If the appeals court refuses, Danco and the Biden administration are expected to file urgent applications asking the justices to restore telehealth and mail access while the case proceeds. The Supreme Court previously preserved access to mifepristone in a 2024 case by ruling that anti‑abortion doctors lacked standing, sidestepping the underlying regulatory issues that may now return in a new posture. hklaw +1

The Bigger Picture

The decision marked one of the most sweeping rollbacks of abortion access since Roe v. Wade was overturned in 2022, targeting a method that accounted for more than one in four abortions via telehealth alone in early 2025. nbcnews +1 With medication abortion now central to post‑Dobbs reproductive care and to state‑to‑state workarounds, the pending Supreme Court showdown will test not only the future of abortion access, but also how far federal courts are willing to go in second‑guessing scientific judgments by the nation’s drug regulator.